Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”

Executive Summary

Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14

You may also be interested in...



Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel

Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel